Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060873 · ClinicalTrials.gov registry record
MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial
A clinical trial, sponsored by University of Southern California.
- Recruiting
- Registry status
- 418
- Enrollment target
NCT06060873: Recruiting study, sponsored by University of Southern California.
NCT06060873 is a clinical trial that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 418 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06060873 is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 418 participants
- Enrollment target
Study Summary
This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.
Primary Outcome
The positive predictive value of pre-operatively elevated miRNA-371 levels in predicting active GCT will be determined by pathologic review of RPLND specimens.
Interventions
- OTHER Clinical Stage I Disease
- OTHER Clinical Stage I with relapse, CSII Disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2028-12-08 |
What NCT06060873 shows while recruiting
NCT06060873 is an observational study that tracks outcomes without assigning an intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Clinical Stage I Disease is the first listed.
NCT06060873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06060873 about?
NCT06060873 is a clinical study titled "MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial". This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.
What is the current status of trial NCT06060873?
This trial is currently recruiting. The enrollment target is 418 participants. The study started on 2023-06-08. Estimated completion is 2028-12-08.
What interventions are being tested in trial NCT06060873?
The interventions under investigation include: Clinical Stage I Disease (OTHER), Clinical Stage I with relapse, CSII Disease (OTHER).
Who is sponsoring clinical trial NCT06060873?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI